Graham Foster

Summary

Affiliation: Queen Mary
Country: UK

Publications

  1. ncbi request reprint Management of chronic hepatitis C--time for a change?
    Graham R Foster
    Imperial College Faculty of Medicine at St Mary s, St Mary s Hospital, Praed Street, London W2 1PG, UK
    J Viral Hepat 9:82-3. 2002
  2. ncbi request reprint Review article: pegylated interferons: chemical and clinical differences
    G R Foster
    Hepatobiliary Group, Adult and Pediatric Gastroenterology, Institute of Molecular and Cellular Science, Queen Mary s School of Medicine and Dentistry, Barts and The Royal London Hospital, London, UK
    Aliment Pharmacol Ther 20:825-30. 2004
  3. ncbi request reprint Type I interferons and the innate immune response--more than just antiviral cytokines
    Peter L Smith
    Hepatobiliary Group, Centre for Adult and Paediatric Gastroenterology, Institute of Cell and Molecular Science, Queen Mary s School of Medicine and Dentistry, Barts and The London, UK
    Mol Immunol 42:869-77. 2005
  4. doi request reprint Quality of life considerations for patients with chronic hepatitis C
    G R Foster
    The Liver Unit, Clinical Academic Unit of Digestive Diseases, Barts and the London School of Medicine and Dentistry, Queen Marys University of London, London, UK
    J Viral Hepat 16:605-11. 2009
  5. pmc Nanomedicines in the treatment of chronic hepatitis C--focus on pegylated interferon alpha-2a
    Thea Thomas
    University College London Hospital NHS Trust, London
    Int J Nanomedicine 2:19-24. 2007
  6. doi request reprint Decline in pulmonary function during chronic hepatitis C virus therapy with modified interferon alfa and ribavirin
    G R Foster
    Bart s and the London School of Medicine, Queen Mary s University of London, London, UK
    J Viral Hepat 20:e115-23. 2013
  7. ncbi request reprint Sustained virologic response rates with telaprevir by response after 4 weeks of lead-in therapy in patients with prior treatment failure
    Graham R Foster
    Queen Marys University of London, Institute of Cell and Molecular Science, London, UK
    J Hepatol 58:488-94. 2013
  8. doi request reprint Triple combination treatment for chronic hepatitis C with protease inhibitors, pegylated interferon and ribavirin: 'lead-in or no lead-in'?
    Graham R Foster
    Department of Hepatology, Queen Mary, University of London, London, UK
    Liver Int 32:61-3. 2012
  9. ncbi request reprint Past, present, and future hepatitis C treatments
    Graham R Foster
    Hepatobiliary Group, Department of Adult and Paediatric Gastroenterology, Queen Marys School of Medicine and Dentistry, London, United Kingdom
    Semin Liver Dis 24:97-104. 2004
  10. ncbi request reprint Apoptotic cell death: the caspase-cleavage "gold rush"
    G R Foster
    Queen Mary s School of Medicine and Dentistry, Barts and The London NHS Trust, London E1 2AT, UK
    Lancet 365:1293-4. 2005

Collaborators

Detail Information

Publications44

  1. ncbi request reprint Management of chronic hepatitis C--time for a change?
    Graham R Foster
    Imperial College Faculty of Medicine at St Mary s, St Mary s Hospital, Praed Street, London W2 1PG, UK
    J Viral Hepat 9:82-3. 2002
  2. ncbi request reprint Review article: pegylated interferons: chemical and clinical differences
    G R Foster
    Hepatobiliary Group, Adult and Pediatric Gastroenterology, Institute of Molecular and Cellular Science, Queen Mary s School of Medicine and Dentistry, Barts and The Royal London Hospital, London, UK
    Aliment Pharmacol Ther 20:825-30. 2004
    ....
  3. ncbi request reprint Type I interferons and the innate immune response--more than just antiviral cytokines
    Peter L Smith
    Hepatobiliary Group, Centre for Adult and Paediatric Gastroenterology, Institute of Cell and Molecular Science, Queen Mary s School of Medicine and Dentistry, Barts and The London, UK
    Mol Immunol 42:869-77. 2005
    ....
  4. doi request reprint Quality of life considerations for patients with chronic hepatitis C
    G R Foster
    The Liver Unit, Clinical Academic Unit of Digestive Diseases, Barts and the London School of Medicine and Dentistry, Queen Marys University of London, London, UK
    J Viral Hepat 16:605-11. 2009
    ..Novel agents, with improved adverse effect profiles, may afford more patients the opportunity to achieve a sustained viral response...
  5. pmc Nanomedicines in the treatment of chronic hepatitis C--focus on pegylated interferon alpha-2a
    Thea Thomas
    University College London Hospital NHS Trust, London
    Int J Nanomedicine 2:19-24. 2007
    ..The use in clinical practice is reviewed along with the evidence for both efficiacy, safety, and advantages over standard interferon...
  6. doi request reprint Decline in pulmonary function during chronic hepatitis C virus therapy with modified interferon alfa and ribavirin
    G R Foster
    Bart s and the London School of Medicine, Queen Mary s University of London, London, UK
    J Viral Hepat 20:e115-23. 2013
    ..The underlying mechanism and clinical implications for long-term pulmonary function impairment warrant further research...
  7. ncbi request reprint Sustained virologic response rates with telaprevir by response after 4 weeks of lead-in therapy in patients with prior treatment failure
    Graham R Foster
    Queen Marys University of London, Institute of Cell and Molecular Science, London, UK
    J Hepatol 58:488-94. 2013
    ....
  8. doi request reprint Triple combination treatment for chronic hepatitis C with protease inhibitors, pegylated interferon and ribavirin: 'lead-in or no lead-in'?
    Graham R Foster
    Department of Hepatology, Queen Mary, University of London, London, UK
    Liver Int 32:61-3. 2012
    ..Those opposed to the 'lead-in' phase cite the complexity of the regime and the lack of robust evidence showing an improvement in clinical outcome in those treated in this fashion...
  9. ncbi request reprint Past, present, and future hepatitis C treatments
    Graham R Foster
    Hepatobiliary Group, Department of Adult and Paediatric Gastroenterology, Queen Marys School of Medicine and Dentistry, London, United Kingdom
    Semin Liver Dis 24:97-104. 2004
    ....
  10. ncbi request reprint Apoptotic cell death: the caspase-cleavage "gold rush"
    G R Foster
    Queen Mary s School of Medicine and Dentistry, Barts and The London NHS Trust, London E1 2AT, UK
    Lancet 365:1293-4. 2005
  11. ncbi request reprint Prediction of sustained virological response in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) and ribavirin
    Graham R Foster
    The Royal London Hospital, London, UK
    Scand J Gastroenterol 42:247-55. 2007
    ..The purpose of this study was to model the probability of achieving a sustained virological response in individual patients, taking into consideration various predictive factors...
  12. doi request reprint Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections
    Graham R Foster
    Queen Marys University of London, Blizard Institute of Cellular and Molecular Science, London, UK
    Gastroenterology 141:881-889.e1. 2011
    ..We evaluated antiviral activity of 2 weeks therapy with telaprevir alone, peginterferon alfa-2a and ribavirin (PR), or all 3 drugs (TPR) in treatment-naïve patients with chronic hepatitis C virus (HCV) genotype 2 or 3 infections...
  13. ncbi request reprint Pegylated interferon with ribavirin therapy for chronic infection with the hepatitis C virus
    Graham R Foster
    Department of Adult and Paediatric Gastroenterology, The Royal London Hospital, Turner Street, London, E1 2AD, UK
    Expert Opin Pharmacother 4:685-91. 2003
    ..Their ease of administration, coupled with their improved efficacy, is likely to lead to an increase in the proportion of infected patients who wish to receive treatment...
  14. doi request reprint Pegylated interferons for the treatment of chronic hepatitis C: pharmacological and clinical differences between peginterferon-alpha-2a and peginterferon-alpha-2b
    Graham R Foster
    Queen Mary University of London, The Liver Unit, Blizard Institute of Cellular and Molecular Science, Barts and the London School of Medicine, The Royal London Hospital, London, UK
    Drugs 70:147-65. 2010
    ..Peginterferon plus ribavirin, as the standard of care for patients with chronic hepatitis C, may in the future form the basis of improved treatment regimens that include new, targeted anti-HCV agents to increase SVR rates even further...
  15. ncbi request reprint Hepatitis C virus therapy to date
    Graham Foster
    Queen Mary Hospital, University of London, London, UK
    Antivir Ther 13:3-8. 2008
    ....
  16. ncbi request reprint Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy
    R D'SOUZA
    Hepatobiliary Group, Institute of Cellular and Molecular Science, Queen Mary s School of Medicine and Dentistry, London, United Kingdom
    Am J Gastroenterol 100:1509-15. 2005
    ..Secondly, to assess whether insulin resistance is associated with sustained virological response to antiviral therapy...
  17. ncbi request reprint Discontinuation of pegylated interferon plus ribavirin in patients who are not responding to therapy -- patients' views of early cessation of therapy
    R D'SOUZA
    Department of Gastroenterology, Hepatobiliary Group, Queen Mary s School of Medicine and Dentistry, Barts and The Royal London, London, UK
    Aliment Pharmacol Ther 21:43-7. 2005
    ..Patients who do not show a virological response after 12 weeks of therapy have a low probability of sustained virological response and it is therefore recommended that such patients stop treatment...
  18. ncbi request reprint Negative correlation between intrahepatic expression of hepatitis C antigens and apoptosis despite high-level expression of Fas and HLA antigens
    S Caronia
    Department of Medicine, Imperial College School of Medicine at St Mary s Hospital, London, UK
    J Viral Hepat 11:511-8. 2004
    ....
  19. ncbi request reprint Hepatitis C virus infection: quality of life and side effects of treatment
    G R Foster
    The Liver Unit, Imperial College of Medicine at St Mary s, St Mary s Hospital, London, UK
    J Hepatol 31:250-4. 1999
    ....
  20. doi request reprint Second generation direct antivirals and the way to interferon-free regimens in chronic HCV
    Heather Lewis
    Blizzard Institute of Cell and Molecular Science, Queen Mary University of London, 4 Newark Street, London, E1 2AD, United Kingdom
    Best Pract Res Clin Gastroenterol 26:471-85. 2012
    ..This review will discuss the HCV replication cycle, mechanisms of action of the new direct acting antiviral drugs, results from published trials into their efficacy and the potential for interferon free treatment regimens in the future...
  21. pmc Interferon-alpha2a is sufficient for promoting dendritic cell immunogenicity
    A Tamir
    Department of Immunology, Division of Medicine, Faculty of Medicine, Imperial College at Hammersmith Hospital, London, UK
    Clin Exp Immunol 142:471-80. 2005
    ..These results clarify some of the in vivo findings obtained with IFN-alpha2a and have direct implications for the design of IFN-alpha-based vaccines for immunotherapy...
  22. ncbi request reprint Interferon plus amantadine versus interferon alone in the treatment of naïve patients with chronic hepatitis C: a UK multicentre study
    S Caronia
    Department of Medicine, St Mary's Hospital ICSM, London, UK
    J Hepatol 35:512-6. 2001
    ..05) while the sustained response was 18 and 15%, respectively. CONCLUSIONS: Combination therapy with interferon plus amantadine does not lead to a significant increase in sustained response rates when compared to interferon monotherapy...
  23. ncbi request reprint Therapeutic options for HCV--management of the infected individual
    G R Foster
    The Liver Centre, Imperial College School of Medicine at St Mary s Hospital, London, UK
    Baillieres Best Pract Res Clin Gastroenterol 14:255-64. 2000
    ..New therapies including polyethylene glycol, PEGylated, interferons and combination regimes involving amantadine are currently under evaluation and it is hoped that improved regimes will be developed in the near future...
  24. ncbi request reprint Knowledge of chronic hepatitis C among East London primary care physicians following the Department of Health's educational campaign
    R F C D'Souza
    Hepatobiliary Group, Barts and The London, Queen Mary s School of Medicine and Dentistry, London, UK
    QJM 97:331-6. 2004
    ..In August 2002, the Department of Health (DH) wrote to all general practitioners (GPs) in England about hepatitis C, enclosing an educational booklet...
  25. ncbi request reprint Relationship between serum ferritin, hepatic iron staining, diabetes mellitus and fibrosis progression in patients with chronic hepatitis C
    R F C D'Souza
    Hepatobiliary Group, Institute of Cellular and Molecular Science, Queen Mary s School of Medicine and Dentistry, London, UK
    Aliment Pharmacol Ther 21:519-24. 2005
    ..The increased prevalence of diabetes mellitus has been associated with increased iron deposits in patients with chronic hepatitis C...
  26. doi request reprint Prevalence of chronic viral hepatitis in people of south Asian ethnicity living in England: the prevalence cannot necessarily be predicted from the prevalence in the country of origin
    G Uddin
    Queen Marys University of London, Barts and the London School of Medicine, The Liver Unit, 4 Newark Street, London, UK
    J Viral Hepat 17:327-35. 2010
    ..As prevalence varies both by country and region of origin and over time, the prevalence in migrant communities living in western countries cannot be easily predicted from studies in the country of origin...
  27. ncbi request reprint Hepatitis C virus infection is not associated with a marked increase in the prevalence of ophthalmic morbidity
    M Leyland
    Western Eye Hospital, London, UK
    Eye (Lond) 14:889-91. 2000
    ..Chronic infection with the hepatitis C virus has been reported to cause a wide variety of ophthalmic lesions. The incidence and significance of these lesions in an unselected population has not been assessed...
  28. ncbi request reprint Combination therapy with amantadine and interferon in naïve patients with chronic hepatitis C: meta-analysis of individual patient data from six clinical trials
    Alessandra Mangia
    Division of Gastroenterology, Ospedale Casa Sollievo Sofferenza, IRCCS, San Giovanni Rotondo 71013, Italy
    J Hepatol 40:478-83. 2004
    ..We performed a meta-analysis of the individual patient's data from previous studies...
  29. ncbi request reprint IFN-alpha subtypes differentially affect human T cell motility
    Graham R Foster
    Hepatobiliary Group, Department of Gastroenterology, Queen Mary s School of Medicine and Dentistry at Barts and The Royal London Hospital, United Kingdom
    J Immunol 173:1663-70. 2004
    ..These observations are consistent with the possibility that subtype-specific intracellular signaling pathways are activated by type I IFNs in T lymphocytes...
  30. ncbi request reprint The way forward in HCV treatment--finding the right path
    Michael P Manns
    Department of Gastroenterology, Hepatology and Endocrinology, Medical School of Hannover, Hannover, Germany
    Nat Rev Drug Discov 6:991-1000. 2007
    ..Here we review the specific challenges posed by HCV, and recent developments in the design of vaccines and novel antiviral agents...
  31. ncbi request reprint Health-related quality of life before, during and after combination therapy with interferon and ribavirin in unselected Swedish patients with chronic hepatitis C
    Anna Hollander
    Division of Infectious Diseases, Department of Medicine, Karolinska Institutet at Karolinska University Hospital Huddinge, Stockholm, Sweden
    Scand J Gastroenterol 41:577-85. 2006
    ..To study the relationship between health-related quality of life (HRQOL) and mode of acquisition, treatment discontinuations, drop in haemoglobin levels and treatment outcome in patients with chronic hepatitis C (CHC)...
  32. pmc Diagnosis and treatment of hepatitis C
    Raymond D'Souza
    Digestive Disease Research Centre, Royal London Hospital, Turner Street, London E1 1BB, UK
    J R Soc Med 97:223-5. 2004
  33. pmc Diagnosis and treatment of chronic hepatitis B
    Raymond D'Souza
    Digestive Disease Research Centre, Queen Mary s School of Medicine and Dentistry, Barts and The London NHS Trust, London, UK
    J R Soc Med 97:318-21. 2004
  34. pmc Dengue virus inhibits alpha interferon signaling by reducing STAT2 expression
    Meleri Jones
    DDRC, Queen Mary s School of Medicine and Dentistry, Royal Free and University College Medical School, Rowland Hill St, London NW3 2PF, United Kingdom
    J Virol 79:5414-20. 2005
    ..Collectively, these data show that dengue virus is capable of subverting the human IFN response by down-regulating STAT2 expression...
  35. ncbi request reprint Different activities of type I interferons on hepatitis B virus core promoter regulated transcription
    Ewert Schulte-Frohlinde
    Department of Medicine II of the Technical University of Munich, Germany
    Cytokine 17:214-20. 2002
    ..The characterization of different effects among type I interferons on HBV-regulatory elements may implicate an IFN-subtype-specific role for the pathogenesis and treatment of HBV-infection...
  36. pmc Qualitatively distinct patterns of cytokines are released by human dendritic cells in response to different pathogens
    Karen Scott
    Department of Immunology, Division of Medicine, Faculty of Medicine, Imperial College at Hammersmith Hospital, London, United Kingdom
    Immunology 116:245-54. 2005
    ..These results support the notion that human dendritic cells are plastic in their response to microbial stimuli and that the nature of the pathogen dictates the response of the dendritic cell...
  37. ncbi request reprint Prevalence of hepatitis C-related cirrhosis in elderly Asian patients infected in childhood
    Raymond D'Souza
    Hepatobiliary Group, Department of Adult and Pediatric Gastroenterology, Barts and The London, Queen Mary s School of Medicine and Dentistry, London, United Kingdom
    Clin Gastroenterol Hepatol 3:910-7. 2005
    ....
  38. ncbi request reprint IFN-alpha2 induces leukocyte integrin redistribution, increased adhesion, and migration
    George Avraamides
    Department of Immunology, Division of Medicine, Faculty of Medicine, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Hospital, London W12 0NN, UK
    J Interferon Cytokine Res 27:291-303. 2007
    ..These findings have obvious implications for the role of type I IFNs in the development of inflammatory responses leading to the initiation of adaptive immunity...
  39. ncbi request reprint Advances in the diagnosis and treatment of hepatitis B
    William Alazawi
    The Liver Unit, Barts and the London School of Medicine, London, UK
    Curr Opin Infect Dis 21:508-15. 2008
    ..Although the armament of drugs licensed for its treatment grows, it is increasingly apparent that the efficacy of these drugs is dependent upon much more that their pharmacology...
  40. pmc Chronic exposure to Helicobacter pylori impairs dendritic cell function and inhibits Th1 development
    Peter Mitchell
    Department of Immunology, Division of Medicine, Faculty of Medicine, Imperial College at Hammersmith Hospital, London, United Kingdom
    Infect Immun 75:810-9. 2007
    ..Our results raise the possibility that in chronic H. pylori infection DCs become exhausted after prolonged antigen exposure leading to suboptimal Th1 development. This effect may contribute to persistence of H. pylori infection...
  41. ncbi request reprint High yield expression, refolding, and characterization of recombinant interferon alpha2/alpha8 hybrids in Escherichia coli
    Dimitris Platis
    Imperial College Faculty of Medicine at St Mary s Hospital, South Wharf Road, London W2 1NY, UK
    Protein Expr Purif 31:222-30. 2003
    ....
  42. ncbi request reprint Interferons at age 50: past, current and future impact on biomedicine
    Ernest C Borden
    Taussig Cancer Center, Case Comprehensive Cancer Center, Mellen Center for Multiple Sclerosis, and Lerner Research Institute, The Cleveland Clinic, 9500 Euclid Avenue, Cleveland, Ohio 44195, USA
    Nat Rev Drug Discov 6:975-90. 2007
    ..Our goal is to offer a molecular and clinical perspective that will enable IFNs or their TLR agonist inducers to reach their full clinical potential...
  43. ncbi request reprint Activity of hybrid type I interferons in cells lacking Tyk2: a common region of IFN-alpha 8 induces a response, but IFN-alpha2/8 hybrids can behave like IFN-beta
    Dimitris Platis
    Imperial College Faculty of Medicine at St Mary s Hospital, London W2 1NY, England
    J Interferon Cytokine Res 23:655-66. 2003
    ..This suggests that this hybrid mimics the interactions of IFN-beta with the receptor and also suggests the existence of a distinct binding site(s) on IFNAR for IFN-beta and some hybrid IFN-alphas...
  44. pmc Directed evolution of gene-shuffled IFN-alpha molecules with activity profiles tailored for treatment of chronic viral diseases
    Amy D Brideau-Andersen
    Maxygen, Incorporated, 515 Galveston Drive, Redwood City, CA 94063, USA
    Proc Natl Acad Sci U S A 104:8269-74. 2007
    ....